Technical Analysis for BLRX - BioLineRx Ltd.

Grade Last Price % Change Price Change
grade F 0.366 -0.38% 0.00
BLRX closed down 0.38 percent on Friday, May 24, 2019, on 44 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Flat
See historical BLRX trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 20 DMA Bearish -0.38%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.38%
Oversold Stochastic Weakness -0.38%
Crossed Above 20 DMA Bullish -3.68%
Stochastic Buy Signal Bullish -3.68%
Pocket Pivot Bullish Swing Setup -3.68%
Oversold Stochastic Weakness -3.68%
New 52 Week Closing Low Bearish 3.10%

Older signals for BLRX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates. The company's development pipeline consists of six clinical-stage therapeutic candidates, including BL-1020, which is in Phase II/III clarity trial to enhance cognitive function in schizophrenia patients; BL-1040, a novel polymer solution that is under pivotal CE-Mark registration trial for use in the prevention of pathological cardiac remodeling following a myocardial infarction; and BL-5010, a medical device, which has completed Phase I/II clinical trials for the non-surgical removal of skin lesions. Its development pipeline also includes BL-1021 that is in Phase Ia clinical trial for the treatment of neuropathic pain, or pain that results from damage to nerve fibers; BL-7040, which is in Phase II clinical trial for the treatment of inflammatory bowel disease; and BL-8040, a peptide that has completed Phase I/II clinical trial for the treatment of acute myeloid leukemia and other hematological cancers. The company also has six products in various pre-clinical development stages for indications, such as central nervous system diseases, infectious diseases, cardiovascular, and autoimmune diseases. In addition, it operates a biotechnology incubator to evaluate therapeutic candidates. BioLineRx Ltd. has license agreements with Genoscience; Compugen Ltd.; RFS Pharma; Yissum and University of Genoa, Italy; Gestion Univalor, Limited Partnership; Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.; and Ikaria. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Biotechnology Health Pain Infectious Diseases Autoimmune Diseases Drug Discovery Clinical Trial Pharmacology Schizophrenia Acute Myeloid Leukemia Inflammatory Bowel Disease Design Of Experiments Clinical Research Central Nervous System Diseases Hematological Cancers Treatment Of Acute Myeloid Leukemia Biotechnology Companies Compugen Treatment Of Inflammatory Bowel Disease
Is BLRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.84
52 Week Low 0.35
Average Volume 1,055,260
200-Day Moving Average 0.647
50-Day Moving Average 0.3971
20-Day Moving Average 0.3712
10-Day Moving Average 0.3646
Average True Range 0.0237
ADX 33.84
+DI 21.0542
-DI 6.4829
Chandelier Exit (Long, 3 ATRs ) 0.3789
Chandelier Exit (Short, 3 ATRs ) 0.4211
Upper Bollinger Band 0.3917
Lower Bollinger Band 0.3507
Percent B (%b) 0.37
BandWidth 11.045259
MACD Line -0.0082
MACD Signal Line -0.0102
MACD Histogram 0.002
Fundamentals Value
Market Cap 35 Million
Num Shares 95.6 Million
EPS -0.28
Price-to-Earnings (P/E) Ratio -1.31
Price-to-Sales 0.00
Price-to-Book 1.78
PEG Ratio 0.18
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.40
Resistance 3 (R3) 0.40 0.39 0.39
Resistance 2 (R2) 0.39 0.38 0.39 0.39
Resistance 1 (R1) 0.38 0.38 0.37 0.38 0.39
Pivot Point 0.37 0.37 0.37 0.37 0.37
Support 1 (S1) 0.36 0.36 0.35 0.36 0.34
Support 2 (S2) 0.35 0.36 0.35 0.34
Support 3 (S3) 0.34 0.35 0.34
Support 4 (S4) 0.34